"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Descriptor ID |
D051997
|
MeSH Number(s) |
D08.811.277.450.430.400.060.500 D12.776.543.550.045
|
Concept/Terms |
ADP-ribosyl Cyclase 1- ADP-ribosyl Cyclase 1
- 1, ADP-ribosyl Cyclase
- ADP ribosyl Cyclase 1
- Cyclase 1, ADP-ribosyl
- T10 Antigen
- Antigen, T10
- NIM-R5 Antigen
- NIM R5 Antigen
- CD38 Antigens
- ADPR Cyclase T10
- Cyclase T10, ADPR
- Acute Lymphoblastic Leukemia Cells Antigen CD38
- Lymphocyte Differentiation Antigen CD38
- Antigens, CD38
- CD38 Antigen
- ADPR Cyclase CD38
- CD38, ADPR Cyclase
- Cyclase CD38, ADPR
|
Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".
Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".
This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1996 | 0 | 2 | 2 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
2000 | 0 | 3 | 3 |
2001 | 0 | 2 | 2 |
2002 | 0 | 4 | 4 |
2003 | 0 | 3 | 3 |
2004 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 2 | 2 |
2008 | 1 | 2 | 3 |
2009 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2012 | 1 | 4 | 5 |
2013 | 3 | 1 | 4 |
2014 | 1 | 2 | 3 |
2015 | 0 | 3 | 3 |
2016 | 0 | 1 | 1 |
2017 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
2019 | 2 | 1 | 3 |
2020 | 0 | 1 | 1 |
2021 | 1 | 1 | 2 |
2022 | 1 | 2 | 3 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.
-
Preclinical characterization of ISB 1342, a CD38?? CD3 T-cell engager for relapsed/refractory multiple?myeloma. Blood. 2023 07 20; 142(3):260-273.
-
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series. Leuk Lymphoma. 2023 04; 64(4):900-903.
-
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 2022 Dec; 27(1):204-207.
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
-
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
-
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. J Immunother Cancer. 2022 01; 10(1).
-
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346.
-
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes. Am J Hematol. 2021 04 01; 96(4):E111-E114.
-
Advancement in monoclonal antibody therapy for multiple myeloma. Lancet Haematol. 2020 May; 7(5):e354-e355.
-
The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells. 2019 12 24; 9(1).